Skip to content
10-Q

Quarterly Report

Lineage Cell Therapeutics, Inc. LCTX

0001193125-26-219479

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 249.3M sh
Shares Diluted Q1 2026 · Mar 31, 2026 261.18M sh
Shares Diluted Q1 2026 · Mar 31, 2025 226.05M sh
Capex Q1 2026 · Mar 31, 2026 $55K
Capex Q1 2026 · Mar 31, 2025 $97K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$8.08M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$4.89M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $35.94M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $40.79M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $47.89M
Stockholders Equity Q1 2026 · Mar 31, 2026 $53.88M
Stockholders Equity Q1 2026 · Dec 31, 2025 $44.55M
Current Liabilities Q1 2026 · Mar 31, 2026 $8.15M
Current Liabilities Q1 2026 · Dec 31, 2025 $11.37M
Total Liabilities Q1 2026 · Mar 31, 2026 $56.84M
Total Liabilities Q1 2026 · Dec 31, 2025 $69.24M
Current Assets Q1 2026 · Mar 31, 2026 $56.16M
Current Assets Q1 2026 · Dec 31, 2025 $59.16M
Total Assets Q1 2026 · Mar 31, 2026 $109.53M
Total Assets Q1 2026 · Dec 31, 2025 $112.58M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.03
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.02
Eps Basic Q1 2026 · Mar 31, 2026 −$0.02
Eps Basic Q1 2026 · Mar 31, 2025 −$0.02
Sga Expense Q1 2026 · Mar 31, 2026 $5.08M
Sga Expense Q1 2026 · Mar 31, 2025 $4.86M
Rd Expense Q1 2026 · Mar 31, 2026 $4.23M
Rd Expense Q1 2026 · Mar 31, 2025 $3.11M
Net Income Q1 2026 · Mar 31, 2026 −$4.81M
Net Income Q1 2026 · Mar 31, 2025 −$4.14M
Operating Income Q1 2026 · Mar 31, 2026 −$7.59M
Operating Income Q1 2026 · Mar 31, 2025 −$6.51M
Revenue Q1 2026 · Mar 31, 2026 $1.73M
Revenue Q1 2026 · Mar 31, 2025 $1.5M
Stock Issued Q1 2026 · Jan 27, 2025 39.47M sh